The Upcoming Antifungal Drugs in Clinical Development for the Treatment of Invasive Candidiasis
Authors:
- Anna ZubovskaiaAZAnna Zubovskaia
- Jose VazquezJose Vazquez
Open Access
- 1 April 2026
- journal article
- review article
- Published by Taylor & Francis in Infection and Drug Resistance
- Vol. ume 19, 1-21
Abstract
Background: Invasive candidiasis (IC) is a major cause of morbidity and mortality among hospitalized patients, and treatment success relies on early diagnosis and prompt initiation of an appropriate antifungal agent. The increasing rates of resistance to first-line antifungal agents (azoles, echinocandins, and polyenes), along with changes in the epidemiology of IC and the spread of multidrug-resistant C. auris, pose further challenges for the management of IC. Limited therapeutic options and routes of administration, drug–drug interactions, and drug toxicities of commonly utilized antifungals further complicate management in the acute hospital setting and create barriers for long-term outpatient treatment. This article provides a review of the current literature on the upcoming antifungal agents that are being actively investigated as treatment options for invasive candidiasis, including those in early- and late-stage clinical development. Areas Covered: We will discuss the spectrum of activity of novel antifungal agents, mechanisms or resistance, pertinent in vivo and vitro data, as well as data from the clinical trials evaluating efficacy and safety of novel antifungals. Expert Opinion: Rezafungin holds promise as an excellent option for outpatient antimicrobial therapy programs due to its favorable safety profile and convenient once-weekly dosing. Ibrexafungerp has broad-spectrum antifungal activity, including activity against fluconazole- and echinocandin-resistant Candida spp. and is available in an oral formulation, making it an attractive option for step-down therapy after treatment with echinocandins or as an alternative to echinocandins. Fosmanogepix has a novel mechanism of action, a favorable side-effect profile, and a broad spectrum of clinical activity. However, further data from clinical trials are necessary to further establish its role in the management of invasive candidiasis. The role of agents in early clinical development, including BAL2062 and ATI2307, as well as repurposed agents with antifungal activity, such as miltefosine, in the management of invasive candidiasis remains to be determined.Keywords
This publication has 139 references indexed in Scilit:
- It’s Here, It’s There, There’s Fungi Everywhere: A Case Series Utilizing Rezafungin for Invasive CandidiasisInfectious Diseases and Therapy, 2025
- Ibrexafungerp: A narrative overviewCurrent Research in Microbial Sciences, 2024
- Management of invasive candidiasis: A focus on rezafungin, ibrexafungerp, and fosmanogepixPharmacotherapy: The Journal of Human Pharmacology and Drug Therapy, 2024
- The Role of Novel Antifungals in the Management of Candidiasis: A Clinical PerspectiveMycopathologia, 2023
- Phase 3 study evaluating the safety and efficacy of oteseconazole in the treatment of recurrent vulvovaginal candidiasis and acute vulvovaginal candidiasis infectionsAmerican Journal of Obstetrics and Gynecology, 2022
- ΔF659 and F659S substitutions at the HS1 of FKS2 gene, along with E655A and W715L upstream and downstream substitutions, correlate with high ibrexafungerp MICs against Candida glabrataClinical Microbiology and Infection, 2022
- In vitro activity of ibrexafungerp against Candida species isolated from blood cultures. Determination of wild-type populations using the EUCAST methodClinical Microbiology and Infection, 2022
- The Antifungal Pipeline: Fosmanogepix, Ibrexafungerp, Olorofim, Opelconazole, and RezafunginDrugs, 2021
- A phase 2, randomized, double-blind, placebo-controlled, dose-ranging study to evaluate the efficacy and safety of orally administered VT-1161 in the treatment of recurrent vulvovaginal candidiasisAmerican Journal of Obstetrics and Gynecology, 2018
- Echinocandin Resistance in Candida Species: a Review of Recent DevelopmentsCurrent Infectious Disease Reports, 2016